InvestorsHub Logo
Followers 1
Posts 103
Boards Moderated 0
Alias Born 03/08/2008

Re: None

Wednesday, 05/09/2018 12:26:13 PM

Wednesday, May 09, 2018 12:26:13 PM

Post# of 70
10-Q for 1Q 2018 filed yesterday. Phase 2 clinical results are anticipated in 2018 for KD025, the ROCK2 inhibitor. Phase 2 enrollment for tesevatinib, the tyrosine kinase inhiitor.

Revenue is only $0.4 for 1Q 2018 compared to $5.6 for 1Q 2017. R&D expenses were up but general administration expenses were down.

1Q 2018 loss from operations was $17.9 vs. $13.9 million for 1Q 2017.